A. Nesbitt

发表

Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent

A. Nesbitt, S. Stephens, E. Chartash, 2009 .

Functional heterogeneity of CD4+ T lymphocytes: two subpopulations with counteracting immunoregulatory functions identified with the monoclonal antibodies WR16 and WR19.

A. Nesbitt, K. Moore, 1987, Immunology.

Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

A. Nesbitt, S. Stephens, M. Sopwith, 1995, Immunology.

Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents

A. Nesbitt, S. Stephens, R. Foulkes, 2007, Inflammatory bowel diseases.

A new generation of high-affinity humanized PEGylated Fab´ fragment anti-tumor necrosis factor-α monoclonal antibodies

G. Kollias, A. Nesbitt, S. Stephens, 2006 .

Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies.

T. Hardingham, B. Henderson, A. Nesbitt, 1995, Annals of the rheumatic diseases.

The effects of anti–TNF agents on the expansion of T helper-type 17 cells driven by lipopolysaccharide-stimulated monocytes

A. Nesbitt, G. Fossati, L. Healy, 2012, Journal of Translational Medicine.

The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody.

A. Nesbitt, S. Stephens, R. Foulkes, 2011, Toxicological sciences : an official journal of the Society of Toxicology.

Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.

Terry S Baker, A. Nesbitt, L. Kevorkian, 2016, Journal of reproductive immunology.

Placental Transfer and Accumulation in Milk of the Anti-TNF Antibody TN3 in Rats: Immunoglobulin G1 Versus PEGylated Fabʼ

A. Nesbitt, S. Stephens, R. Foulkes, 2006 .

Effect of the Anti-TNF Agents, Adalimumab, Etanercept, Infliximab, and Certolizumab PEGOL (CDP870) on the Induction of Apoptosis in Activated Peripheral Blood Lymphocytes and Monocytes: 806

A. Nesbitt, G. Fossati, 2005 .

Identification and isolation of OKT4+ suppressor cells with the monoclonal antibody WR16.

A. Nesbitt, K. Moore, 1986, Immunology.

The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.

J. Emtage, A. Nesbitt, M. Bodmer, 1995, Immunology.

The PEG Moiety of Certolizumab Pegol is Rapidly Cleared from the Blood of Humans by the Kidneys Once it is Cleaved from the Fabʼ: 1195

A. Nesbitt, L. King, T. Parton, 2009 .

Investigation of the Distribution and Elimination of the PEG Component of Certolizumab Pegol in Rats: 1105

A. Nesbitt, L. King, S. Heywood, 2008 .

P068 Investigation of the Distribution and Elimination of the PEG Component of Certolizumab Pegol in Rats

A. Nesbitt, L. King, S. Heywood, 2008 .

Neutralizing antibodies to certolizumab pegol do not appear to affect efficacy and safety in patients with Crohnʼs disease: P-055.

A. Nesbitt, S. Stephens, R. Bloomfield, 2008 .

P-0072: PEG component of certolizumab pegol inhibits stimulated mast cell degranulation

A. Nesbitt, M. Bracher, S. Lamour, 2009 .

PEG Component of Certolizumab Pegol Inhibits Stimulated Mast Cell Degranulation: 1198

A. Nesbitt, M. Bracher, S. Lamour, 2009 .

Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays

A. Nesbitt, G. Fossati, 2010, Journal of Translational Medicine.

W1208 No Significant Transfer of Certolizumab Pegol Compared With IgG in the Perfused Human Placenta In Vitro

A. Nesbitt, S. Urbaniak, S. Armstrong-Fisher, 2010 .

Prolonged in vivo residence times of antibody fragments associated with albumin.

A. Nesbitt, A. Suitters, A. P. Chapman, 2001, Bioconjugate chemistry.

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.

A. Nesbitt, A. Moore, R. Palframan, 2009, Journal of immunological methods.

Splice variants of human FOXP3 are functional inhibitors of human CD4+ T‐cell activation

Emma L. Smith, F. Ramsdell, M. Robinson, 2006, Immunology.

A PEGylated Fab’ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease

A. Nesbitt, G. Fossati, T. Bourne, 2012, BioDrugs.

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept

A. Nesbitt, H. Gong, Alistair J Henry, 2011, Journal of Translational Medicine.

Reverse signalling of membrane TNF in human natural killer cells: a comparison of the effect of certolizumab pegol and other anti-TNF agents

A. Nesbitt, G. Fossati, 2011, Journal of Translational Medicine.

In Vitro Complement-Dependent Cytotoxicity and Antibody-Dependent Cellular Cytotoxicity by the Anti-TNF Agents Adalimumab, Etanercept, Infliximab, and Certolizumab Pegol (CDP870): 807

A. Nesbitt, G. Fossati, 2005 .

The levels of TLR2, TLR4 and CD14 on LPS stimulated monocytes are reduced by membrane TNF signaling of certolizumab pegol, adalimumab and infliximab: O-0032.

A. Nesbitt, G. Fossati, 2008 .

Anti-major histocompatibility complex class II treatment prevents graft rejection in the hamster-to-rat cardiac xenograft.

A. Nesbitt, K. Zinkewich-Péotti, H. Ladyman, 1999, Transplantation.

Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated Fabʼ fragment in rats: P-0030

A. Nesbitt, S. Stephens, R. Foulkes, 2007 .

Effect of certolizumab pegol, etanercept, adalimumab and infliximab on cytokine production: P-0029

A. Nesbitt, G. Fossati, D. Brown, 2007 .

Formatting antibody fragments to mediate specific therapeutic functions.

A. Nesbitt, A. N. Weir, A. P. Chapman, 2002, Biochemical Society transactions.

The in vivo and in vitro characterisation of an engineered human antibody to E-selectin.

S. Albelda, W. Buurman, M. Robinson, 1997, Immunotechnology : an international journal of immunological engineering.

TNF Binding by Certolizumab Pegol, Adalimumab, and Infliximab-Stoichiometry, Complex Formation, and the Biologic Effects of Complexes

A. Nesbitt, Jeff Kennedy, G. Fossati, 2007 .

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.

A. Nesbitt, A. Moore, R. Palframan, 2009, Journal of immunological methods.